Lyrica
Product Images NDC 0071-1015

Product Visual Gallery

This gallery contains 34 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 0071-1015). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Parke-davis Div Of Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cockcroft And Gault Equation (Lyrica 01)

A formula illustrating the calculation of Creatinine Clearance (CLCr) based on age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor of 0.85 for female patients. The equation is displayed with variables and arithmetic operations.*

FDA Label Image

Chemical Structure (Lyrica 02)

Chemical structure diagram of pregabalin, the active ingredient in Lyrica 300 mg. The diagram depicts the molecular structure showing carboxylic acid (CO2H) and amine (NH2) groups.*

FDA Label Image

Figure 1 (Lyrica 03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Lyrica (pregabalin) at doses of 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and placebo. The graph compares effectiveness in pain improvement across these treatment groups.*

FDA Label Image

Figure 2 (Lyrica 04)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline, illustrating data for Pregabalin 100 mg three times a day and a placebo. The y-axis represents the percent of patients improved, and the x-axis shows the percent improvement in pain from baseline.*

FDA Label Image

Figure 3 (Lyrica 05)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. The graph compares outcomes for patients taking pregabalin at doses of 75 mg, 150 mg, and 300 mg twice daily, along with a placebo group.*

FDA Label Image

Figure 4 (Lyrica 06)

A line graph comparing the percent of patients improved against percent improvement in pain from baseline for Lyrica (pregabalin) at 100 mg and 200 mg three times a day, and a placebo.*

FDA Label Image

Figure 5 (Lyrica 07)

A line graph showing the percent of patients improved in pain from baseline, comparing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The x-axis represents percent improvement in pain from baseline, while the y-axis indicates the percent of patients improved. Two vertical lines mark values approximately at 30% and 50% improvement.*

FDA Label Image

Figure 6 (Lyrica 08)

A bar chart comparing responder rates (%) across different dosages of Lyrica (pregabalin) and placebo in two studies labeled Study E1 and Study E3. The x-axis indicates placebo and varying daily doses in mg, while the y-axis shows response rate percentages. Significant increases compared to placebo are marked.*

FDA Label Image

Figure 7 (Lyrica 09)

A graph showing the median percent reduction in seizure frequency from baseline versus dose (mg/day) for Lyrica at 300 mg/day in three studies identified as E1, E2, and E3 with BID and TID dosing. The graph includes symbols representing study data points and indicates p-values showing statistical significance for dose-related seizure reductions compared to placebo.*

FDA Label Image

Figure 8 (Lyrica 10)

A bar chart comparing responder rates (%) among three groups: Placebo (22.6%), 2.5 mg/kg/day dose (29.1%), and 10 mg/kg/day dose (40.6%). The number of subjects in each group is shown below the bars: Placebo (93), 2.5 mg/kg/day (103), and 10 mg/kg/day (96).*

FDA Label Image

Figure 9 (Lyrica 11)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 600 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo, with percent of patients improved decreasing as percent improvement in pain increases.*

FDA Label Image

Figure 10 (Lyrica 12)

A Kaplan-Meier survival curve showing the estimated percentage of subjects without LTR over 180 days, comparing Pregabalin treatment (solid line) versus Placebo (dashed line). The y-axis represents the estimated percentage of subjects without LTR, and the x-axis shows time in days.*

FDA Label Image

Figure 11 (Lyrica 13)

A line graph showing the percent of subjects improved versus percent improvement from baseline to Week 12 BOCF. Two lines represent Pregabalin and Placebo groups, with the Pregabalin group showing consistently higher percentages of subjects improved across the range compared to the Placebo group.*

FDA Label Image

Logo (Lyrica 14)

A line chart comparing the percentage of subjects improved over time between Pregabalin and Placebo groups from baseline to Week 16, with the x-axis representing percent improved and the y-axis showing the percent of subjects improved.*

FDA Label Image

Lyrica 14a

FDA Label Image

Lyrica 14b

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle Label)

Lyrica 25 mg capsules label showing pregabalin as the active ingredient. The label includes storage instructions, manufacturer information for Parke-Davis Division of Pfizer Inc, and indicates a quantity of 90 capsules. It is marked Rx only and advises dispensing with a medication guide.*

FDA Label Image

Principal Display Panel (50 mg Capsule Blister Pack)

Labels for Lyrica 50 mg capsules showing the proprietary name, active ingredient pregabalin, strength, dosage form, and distribution by Parke-Davis Div of Pfizer Inc. Each label includes identifiers such as lot number, expiration date, and barcode for packaging.*

FDA Label Image

Principal Display Panel (50 mg Capsule Blister Pack Carton)

Lyrica 50 mg capsules packaging label by Parke-Davis Div of Pfizer Inc showing the unit dose carton for 100 capsules. Label features the proprietary name Lyrica and active ingredient pregabalin with a designation of 50 mg strength. The design includes Pfizer logo, controlled substance symbol (C V), barcodes, storage instructions, and indication for in-institution use only.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

Lyrica 50 mg capsules label by Parke-Davis Division of Pfizer Inc. The label shows the proprietary name Lyrica with the active ingredient pregabalin, dosage strength 50 mg, and package size of 90 capsules. Storage and dispensing instructions are included, along with the NDC number 0071-1013-68 and a barcode. The product is identified as Rx only, made in Singapore.*

FDA Label Image

Principal Display Panel (75 mg Capsule Blister Pack)

Multiple printed capsule labels for Lyrica 75 mg (pregabalin) from Parke-Davis Div of Pfizer Inc. Each label displays the product name, strength, dosage form (capsule), and includes barcodes and distributor information. The labels appear arranged for cutting or packaging use.*

FDA Label Image

Principal Display Panel (75 mg Capsule Blister Pack Carton)

Packaging label for Lyrica 75 mg (pregabalin) capsules by Parke-Davis Division of Pfizer Inc. The label indicates a unit dose format for in-institution use only, with a quantity of 100 capsules. It includes instructions to dispense with medication guide and storage recommendations, and states the product is made in Singapore.*

FDA Label Image

Principal Display Panel (75 mg Capsule Bottle Label)

Lyrica 75 mg capsules label by Parke-Davis Division of Pfizer Inc. The label shows the proprietary name Lyrica and active ingredient pregabalin, with a strength of 75 mg. It indicates the package contains 90 capsules and is Rx only. Storage instructions and dispensing information are provided along with a barcode and batch identifiers.*

FDA Label Image

Principal Display Panel (100 mg Capsule Blister Pack)

Packaging label for Lyrica 100 mg capsules featuring the brand name, active ingredient pregabalin, capsule dosage form, and distribution information by Parke-Davis Div of Pfizer Inc, NY. The label displays barcodes, lot numbers, and expiration date placeholders. Several identical labels appear arranged in a grid pattern.*

FDA Label Image

Principal Display Panel (100 mg Capsule Blister Pack Carton)

The packaging label for Lyrica (pregabalin) capsules shows a 100 mg strength in a unit dose format. The box indicates it contains 100 capsules for in-institution use only, with the labeler as Parke-Davis Division of Pfizer Inc. The design includes the Pfizer logo, dosage strength highlighted in orange, and storage and usage instructions printed on the side.*

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle Label)

Lyrica 100 mg capsules label from Parke-Davis Div of Pfizer Inc. The label includes storage instructions at 25°C (77°F) with permitted excursions, dispensing instructions, dosage unit contents (100 mg pregabalin per capsule), and packaging details for 90 capsules. It also features the Pfizer logo and standard drug dispensing warnings with NDC 0071-1015-68.*

FDA Label Image

Principal Display Panel (150 mg Capsule Blister Pack)

Lyrica 150 mg capsule label displaying pregabalin as the active ingredient. The label includes dosage strength, capsule form, and manufacturer information: Parke-Davis Div of Pfizer Inc, NY. Multiple identical label sections are visible on a single sheet with barcodes and regulatory numbers.*

FDA Label Image

Principal Display Panel (150 mg Capsule Blister Pack Carton)

Packaging label for Lyrica 150 mg capsules by Parke-Davis Division of Pfizer Inc. The label indicates pregabalin as the active ingredient, with 100 capsules per unit dose package. It includes the Pfizer logo, dosage strength in mg, usage restriction for in-institution use only, controlled substance schedule (CV), and storage instructions. The label also displays barcodes and regulatory text indicating it is for Rx only and made in Singapore.*

FDA Label Image

Principal Display Panel (150 mg Capsule Bottle Label)

Lyrica 150 mg capsules label by Parke-Davis Division of Pfizer Inc. The label shows the active ingredient pregabalin, with a strength of 150 mg per capsule. It includes storage instructions at 25°C (77°F) with permitted excursions, dispensing instructions, and a note to always dispense with the medication guide. The package contains 90 capsules and indicates prescription use only. The product is made in Singapore.*

FDA Label Image

Principal Display Panel (200 mg Capsule Bottle Label)

Lyrica 200 mg capsules label showing the Pfizer logo with pregabalin as the active ingredient. The label indicates a bottle containing 90 capsules, distributed by Parke-Davis, a division of Pfizer Inc. Storage instructions specify 25°C with permitted excursions, and the label includes directions to dispense with medication guide and that the product is Rx only.*

FDA Label Image

Principal Display Panel (225 mg Capsule Bottle Label)

The image shows a label for Lyrica capsules containing 225 mg of pregabalin. It is distributed by Parke-Davis Division of Pfizer Inc. The label includes storage instructions, dosage information advising to see accompanying prescribing information, and states the product is made in Singapore. The package size is 90 capsules, and it is marked Rx only.*

FDA Label Image

Principal Display Panel (300 mg Capsule Bottle Label)

Lyrica 300 mg capsules label showing the active ingredient pregabalin. The label includes storage instructions, dosage, and usage notes, with a quantity of 90 capsules. Labeler is Parke-Davis Division of Pfizer Inc. The label features the Pfizer logo and provides barcode and lot number information.*

FDA Label Image

Principal Display Panel (20 mg Bottle Label)

Label for Lyrica (pregabalin) 20 mg per mL oral solution, 16 fl oz (473 mL) bottle. Distributed by Parke-Davis, a division of Pfizer Inc. The label includes storage instructions, dosage form, concentration, and regulatory information. Product is made in Singapore and labeled Rx only.*

FDA Label Image

Principal Display Panel (20 mg Bottle Carton)

Packaging label for Lyrica (pregabalin) 20 mg per mL oral solution by Parke-Davis Division of Pfizer Inc. The label includes the drug name, strength, dosage form, storage instructions, and volume of 16 fl oz (473 mL). It also contains a barcode and notes that the product is made in Singapore and for prescription use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.